Endometrial Neoplasms Clinical Trials

23 recruitingLast updated: June 17, 2026

There are 23 actively recruiting endometrial neoplasms clinical trials across 15 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Seoul, South Korea, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Endometrial Neoplasms Trials at a Glance

23 actively recruiting trials for endometrial neoplasms are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Seoul, Boston, and Houston. Lead sponsors running endometrial neoplasms studies include Eli Lilly and Company, Yonsei University, and Xiaojun Chen.

Browse endometrial neoplasms trials by phase

Treatments under study

About Endometrial Neoplasms Clinical Trials

Looking for clinical trials for Endometrial Neoplasms? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Endometrial Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Endometrial Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled30 locationsNCT07114601
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 2

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Ovarian NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms+3 more
Yonsei University198 enrolled27 locationsNCT06023862
Recruiting
Not Applicable

Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial

Endometrial Neoplasms
Universita di Verona1,030 enrolled3 locationsNCT05687084
Recruiting
Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Neoplasm MetastasisEndometrial NeoplasmsNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute30 enrolled1 locationNCT06532539
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting

Registry Platform Ovarian and Endometrial Cancer

Ovarian CancerEndometrial CancerCarcinoma+4 more
iOMEDICO AG1,975 enrolled1 locationNCT05129969
Recruiting
Phase 1

A Study of DM002 in Patients With Advanced Solid Tumors

Ovarian NeoplasmsColorectal NeoplasmsEndometrial Neoplasms+2 more
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.160 enrolled5 locationsNCT06751329
Recruiting
Phase 1

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Carcinoma, Non-Small Cell LungOvarian NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company495 enrolled23 locationsNCT06400472
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

MalignancyMelanomaCancer+7 more
Cancer Research UK30 enrolled27 locationsNCT05770102
Recruiting
Phase 1Phase 2

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small Cell LungOvarian NeoplasmsColorectal Neoplasms+3 more
Eli Lilly and Company540 enrolled49 locationsNCT04956640
Recruiting
Phase 2Phase 3

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
Xiaojun Chen80 enrolled2 locationsNCT05316935
Recruiting
Phase 2Phase 3

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

ObesityEndometrial NeoplasmsAtypical Endometrial Hyperplasia+1 more
Xiaojun Chen29 enrolled2 locationsNCT06379113
Recruiting

The Role of POLE Mutation in High Risk Endometrial Cancer.

Endometrial Neoplasms
Far Eastern Memorial Hospital150 enrolled1 locationNCT07114653
Recruiting
Not Applicable

Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue

Sentinel Lymph NodeMetastasisEndometrial Neoplasms+1 more
Dokuz Eylul University100 enrolled2 locationsNCT07040657
Recruiting

DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

Ovarian CancerEndometrial CancerOvarian Neoplasms+6 more
McGill University1,200 enrolled1 locationNCT02288676
Recruiting
Phase 2

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Endometrial CancerEndometrial Neoplasms
Yonsei University30 enrolled1 locationNCT05795244
Recruiting
Phase 2

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Endometrial CancerEndometrial CarcinomaRecurrent Endometrial Carcinoma+2 more
Yonsei University92 enrolled6 locationsNCT06502743
Recruiting
Not Applicable

Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer

Endometrial CancerGynecologic CancerEndometrial Neoplasms+2 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS566 enrolled1 locationNCT05974995
Recruiting

Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study

Endometrial NeoplasmsInflammatory Response
University of Campania Luigi Vanvitelli128 enrolled1 locationNCT05657483